Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Inflammatory Bowel Diseases

Free Subscription 26.08.2024 3 Aliment Pharmacol Ther 3 Am J Gastroenterol 2 BMC Gastroenterol 1 Dig Dis 4 Dig Dis Sci 1 Gastroenterol Hepatol 7 Inflamm Bowel Dis 3 J Crohns Colitis 1 J Pediatr

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Aliment Pharmacol Ther

1. JIANG F, Yang W, Cao Y, Cao X, et al
   The contribution of dietary advanced glycation end-products and genetic risk in the development of inflammatory bowel disease: a prospective cohort study.
   Aliment Pharmacol Ther. 2024 Aug 23. doi: 10.1111/apt.18218.
   PubMed         Abstract available
   
   
2. ZHAO J, Xue E, Zhou S, Zhang M, et al
   Allostatic load increases the incidence and risk of adverse prognosis in inflammatory bowel disease.
   Aliment Pharmacol Ther. 2024 Aug 21. doi: 10.1111/apt.18217.
   PubMed         Abstract available
   
   
3. GIBSON PR, Yao CK, Halmos EP
   Review article: Evidence-based dietary management of inflammatory bowel disease.
   Aliment Pharmacol Ther. 2024 Aug 20. doi: 10.1111/apt.18214.
   PubMed         Abstract available
   
   

   
   Am J Gastroenterol

4. VLADIMIROVA N, Moller J, Attauabi M, Madsen G, et al
   Spine and sacroiliac joint involvement in newly diagnosed inflammatory bowel disease patients - clinical and magnetic resonance imaging findings from a population-based cohort.
   Am J Gastroenterol. 2024 Aug 20. doi: 10.14309/ajg.0000000000003039.
   PubMed         Abstract available
   
   
5. NAUDE C, Skvarc D, Maunick B, Evans S, et al
   Acceptance & Commitment Therapy for Adults Living With Inflammatory Bowel Disease & Distress: A Randomized Controlled Trial.
   Am J Gastroenterol. 2024 Aug 20. doi: 10.14309/ajg.0000000000003032.
   PubMed         Abstract available
   
   
6. DAI C, Huang YH, Jiang M
   Comparative Risk of Serious Infection With Vedolizumab vs Anti-Tumor Necrosis Factors in Inflammatory Bowel Disease.
   Am J Gastroenterol. 2024 Aug 19. doi: 10.14309/ajg.0000000000002995.
   PubMed        
   
   

   
   BMC Gastroenterol

7. LONG X, Peng C, Zhang X, Kong W, et al
   Different imaging techniques' diagnostic efficacy for Crohn's disease activity and external validation and comparison of MDCTAs, SES-CD and IBUSSAS.
   BMC Gastroenterol. 2024;24:277.
   PubMed         Abstract available
   
   
8. YOON H, Ye BD, Kang SB, Lee KM, et al
   Safety and effectiveness of tofacitinib in Korean adult patients with ulcerative colitis: post-marketing surveillance study.
   BMC Gastroenterol. 2024;24:273.
   PubMed         Abstract available
   
   

   
   Dig Dis

9. GINARD D, Barreiro-de Acosta M, Nos P, Moraleja I, et al
   Efficacy of beclomethasone dipropionate in lowering fecal calprotectin levels in patients with ulcerative colitis in clinical remission and at risk of relapse: The Becalcu randomized, controlled trial.
   Dig Dis. 2024 Aug 22. doi: 10.1159/000540792.
   PubMed         Abstract available
   
   

   
   Dig Dis Sci

10. ALPEREN CC, Soydas B, Serin E, Erbayrak M, et al
    Role of Environmental Risk Factors in the Etiology of Inflammatory Bowel Diseases: A Multicenter Study.
    Dig Dis Sci. 2024;69:2927-2936.
    PubMed         Abstract available
    
    
11. MAHMOUD M, Syn WK
    Impact of Obesity and Metabolic Syndrome on IBD Outcomes.
    Dig Dis Sci. 2024;69:2741-2753.
    PubMed         Abstract available
    
    
12. LOCKMAN S, Tandon P
    Low-Dose Aspirin Use in Pregnancy in Patients with IBD with Risk Factors for Preeclampsia: A Retrospective Cohort Study.
    Dig Dis Sci. 2024;69:2719-2720.
    PubMed        
    
    
13. HARINDRANATH S
    Tofacitinib in Ulcerative Colitis - Second-Line Therapy, First-Rate Results.
    Dig Dis Sci. 2024 Aug 22. doi: 10.1007/s10620-024-08589.
    PubMed        
    
    

    
    Gastroenterol Hepatol

14. DIAZ MOLINA RJ, Comesana Castellar C, Crespi Rigo J, Radu Tomsa C, et al
    DESCRIPTIVE OBSERVATIONAL STUDY ON THE USE OF VIRTUAL REALITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE UNDERGOING BIOLOGICAL TREATMENT.
    Gastroenterol Hepatol. 2024 Aug 20:502236. doi: 10.1016/j.gastrohep.2024.502236.
    PubMed         Abstract available
    
    

    
    Inflamm Bowel Dis

15. GROSEN A, Bellaguarda E, Liljeqvist-Soltic I, Skytte AB, et al
    Tofacitinib Does Not Impair Sperm Quality in Men With Ulcerative Colitis.
    Inflamm Bowel Dis. 2024 Aug 23:izae195. doi: 10.1093.
    PubMed        
    
    
16. MINAWALA R, Kim M, Delau O, Ghiasian G, et al
    Sarcopenia Is a Risk Factor for Postoperative Complications Among Older Adults With Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Aug 23:izae187. doi: 10.1093.
    PubMed         Abstract available
    
    
17. DAY AS, Ballard TM, Yao CK, Gibson PR, et al
    Food-Based Interventions as Therapy for Inflammatory Bowel Disease: Important Steps in Diet Trial Design and Reporting of Outcomes.
    Inflamm Bowel Dis. 2024 Aug 23:izae185. doi: 10.1093.
    PubMed         Abstract available
    
    
18. HINNANT L, Rios Villacorta N, Chen E, Bacchus D, et al
    Consensus Statement on Managing Anxiety and Depression in Individuals with Inflammatory Bowel Disease.
    Inflamm Bowel Dis. 2024 Aug 22:izae151. doi: 10.1093.
    PubMed         Abstract available
    
    
19. NEIMAN N, Boothroyd D, Anjur K, Bensen R, et al
    Self-Compassion in Adolescents and Young Adults With Inflammatory Bowel Disease: Relationship of Self-Compassion to Psychosocial and Physical Outcomes.
    Inflamm Bowel Dis. 2024 Aug 21:izae170. doi: 10.1093.
    PubMed         Abstract available
    
    
20. DALAL RS, Allegretti JR
    Reply: In Severe Inflammatory Bowel Disease, the Onset of Effectiveness of Biologics and Small Molecules Depends More on the Medication Than on the Diagnosis.
    Inflamm Bowel Dis. 2024 Aug 20:izae181. doi: 10.1093.
    PubMed        
    
    
21. ATTAUABI M, Burisch J, Nielsen OH, Seidelin JB, et al
    In Severe Inflammatory Bowel Disease, the Onset of Effectiveness of Biologics and Small Molecules Depends More on the Medication Than on the Diagnosis.
    Inflamm Bowel Dis. 2024 Aug 20:izae183. doi: 10.1093.
    PubMed        
    
    

    
    J Crohns Colitis

22. YERUSHALMY-FELER A, Lujan R, Loewenberg Weisband Y, Greenfeld S, et al
    Peripheral Blood Eosinophilia at Diagnosis of Inflammatory Bowel Disease Is Associated with Severe Disease Course; A Nationwide Study From the epi-IIRN Cohort.
    J Crohns Colitis. 2024 Aug 23:jjae130. doi: 10.1093.
    PubMed         Abstract available
    
    
23. IBORRA M, Caballol B, Garrido A, Huguet JM, et al
    Subcutaneous infliximab cut-off points in patients with inflammatory bowel disease. Data from the ENEIDA registry.
    J Crohns Colitis. 2024 Aug 22:jjae127. doi: 10.1093.
    PubMed         Abstract available
    
    
24. REPPELL M, Zheng X, Dreher I, Blaes J, et al
    HLA-DQA1*05 associates with anti-TNF immunogenicity and low adalimumab trough concentrations in inflammatory bowel disease patients from the SERENE UC and CD studies.
    J Crohns Colitis. 2024 Aug 20:jjae129. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    J Pediatr

25. CRUZ BL, Rosales D, Chuang J, Cruz R, et al
    Cross-sectional Evaluation of Health Insurance Knowledge and Self-efficacy in Adolescents and Young Adults with Inflammatory Bowel Disease.
    J Pediatr. 2024 Aug 14:114244. doi: 10.1016/j.jpeds.2024.114244.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Inflammatory Bowel Diseases is free of charge.